GRACE is pleased to announce the acceptance of two rising stars in to the inaugural GRACE Fellows Ambassador Program for the 2019-2020 Program Year...
Dr. Sarah Goldberg from Yale Cancer Center describes which molecular markers she seeks for NSCLC patients.
[powerpress]
Dr. Heather Wakelee, from Stanford University, discusses the evidence and her personal interpretation and recommended approach to maintenance therapy for advanced non-small cell lung cancer.
[powerpress]
Dr. Ravi Salgia, University of Chicago, provides his perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.
[powerpress]
Dr. Karen Kelly, of the University of California, Davis expresses her practice pattern for patients with advanced non-small cell lung cancer who would need a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.
[powerpress]
Dr. David Spigel, Sarah Cannon Cancer Center, offers his insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent.
[powerpress]
Dr. Rosalyn Juergens, McMaster University, reviews her thought process in recommending a repeat biopsy after progression for patients with advanced lung cancer.
[powerpress]
Dr. Sarah Goldberg, from Yale Cancer Center, offers her view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified during first line chemotherapy. When should we switch treatments?
[powerpress]
Dr. Phil Bonomi, from Rush University, discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.
[powerpress]
Drs. Ross Camidge and Corey Langer describe which patients with advanced NSCLC they seek molecular marker testing on, and the particular markers they prioritize.
[powerpress]
Dr. Ravi Salgia, University of Chicago, describes the CollabRx system, which matches patients with particular mutations to appropriate clinical trials.
[powerpress]
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.